WALTHAM, Mass. and DUBLIN, Ireland, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA) (“ Mural ”) today announced that its shareholders have voted to approve the previously announced proposed acquisition of Mural by XRA 5 Corp. (“ Sub ”), a wholly owned subsidiary of XOMA Royalty Corporation (Nasdaq: XOMA) (“ XOMA Royalty ”). As described in more detail below, a majority in number of the shareholders of... Read More

WALTHAM, Mass. and DUBLIN, Ireland, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (Nasdaq: MURA) (“ Mural ”), a clinical-stage immuno-oncology company, today announces for the purposes of the Irish Takeover Panel Act, 1997, Takeover Rules 2022 (the “ Irish Takeover Rules ”), that it has published the definitive proxy statement of Mural relating to the Acquisition described below, which also constitutes a scheme... Read More

WALTHAM, Mass., DUBLIN, Ireland and EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company (“ Mural ”), and XOMA Royalty Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator (“ XOMA Royalty ”), announced today they have entered into a definitive agreement pursuant to which XRA 5 Corp., a newly formed company wholly owned by XOMA Royalty (“... Read More

Mural continues to explore strategic alternatives Estimates cash and cash equivalents of approximately $43 to $48 million at December 31, 2025, if it has not consummated a transaction or other strategic alternative by year end WALTHAM, Mass. and DUBLIN, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), today announced its financial results for the second quarter of 2025 and provided a business update. On... Read More

Following review of data from the phase 2 ARTISTRY-6 trial and previously announced results from the phase 3 ARTISTRY-7 trial, Mural will discontinue all clinical development of nemvaleukin With $144.4 million in cash as of December 31, 2024, Mural plans to explore strategic alternatives and will undertake a reduction in force of approximately 90% of employees WALTHAM, Mass. and DUBLIN, April 15, 2025 (GLOBE NEWSWIRE) --... Read More

Based on overall survival data observed in interim analysis in platinum-resistant ovarian cancer, Mural will not progress trial to final analysis Continued demonstration of favorable tolerability profile generally consistent with previously reported data; over 800 patients treated across the greater nemvaleukin clinical program The company remains on track to share topline results from potentially registrational, phase 2... Read More

Interim analysis of overall survival in potentially registrational phase 3 ARTISTRY-7 trial in platinum-resistant ovarian cancer expected in late Q1/early Q2 2025 Top-line data readout of potentially registrational phase 2 ARTISTRY-6 (cohort 2) trial in mucosal melanoma expected in Q2 2025 Preliminary data readouts for less-frequent intravenous dosing of nemvaleukin alfa in the ARTISTRY-6 trial in patients with cutaneous... Read More

WALTHAM, Mass and DUBLIN, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered therapies targeting cytokine pathways, today announced that CEO Caroline Loew, Ph.D., will present at the TD Cowen 45 th Annual Health Care Conference on March 4, 2025 and 3:10 p.m. ET. A live webcast of the presentation will be available at... Read More

Readouts for two late-stage, potentially registrational trials of nemvaleukin alfa expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma Preliminary data readouts for less-frequent intravenous dosing of nemvaleukin in patients with cutaneous melanoma expected in 1H 2025 for monotherapy, with patient enrollment now complete, and 2H 2025 for combination therapy Mural nominated... Read More

WALTHAM, Mass and DUBLIN, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that on December 2, the Company granted to four newly hired employees (i) non-statutory stock options to purchase an aggregate of... Read More

Nemvaleukin was generally well tolerated in ARTISTRY-1, a completed phase 1/2 clinical trial, with durable responses observed in both monotherapy and combination therapy across a range of heavily pretreated advanced solid tumors, including in platinum-resistant ovarian cancer (PROC), which does not typically respond to immunotherapies Safety profile and anti-tumor activity observed in ARTISTRY-1 supported the company’s two... Read More

Company remains on track in late-stage, potentially registrational trials of nemvaleukin alfa, with data readouts expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma Candidate nominations for IL-18 and IL-12 programs expected in Q4 2024, and IND submission for Mural’s IL-18 program planned for Q4 2025 Mural reiterates guidance on projected cash runway into Q4 2025 WALTHAM,... Read More

WALTHAM, Mass. and DUBLIN, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that members of the management team will participate in two upcoming investor conferences. Jefferies London Healthcare Conference... Read More

Less frequent IV dosing with nemvaleukin in patients with select advanced solid tumors, including ovarian cancer and mucosal melanoma, showed tumor site-specific pharmacodynamic activity and immune activation Preclinical data demonstrated durable immune responses and tumor growth inhibition with Mural’s IL-18 variants, reinforcing pursuit of IND-enabling studies with candidate nomination anticipated by the end of 2024, and... Read More

WALTHAM, Mass and DUBLIN, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that on November 1, the Company granted to five newly hired employees (i) non-statutory stock options to purchase an aggregate of... Read More

WALTHAM, Mass and DUBLIN, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced three upcoming poster presentations at the 39 th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) taking place... Read More

WALTHAM, Mass. and DUBLIN, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that on October 1, the Company granted to three newly hired employees (i) non-statutory stock options to purchase an aggregate of... Read More

Key data readouts for the company’s late-stage, potentially registrational trials of nemvaleukin are expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma Management team to provide additional information not previously disclosed related to nemvaleukin study design, statistical assumptions, and study execution Clinicians to discuss treatment landscape of platinum-resistant... Read More

WALTHAM, Mass and DUBLIN, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced the appointment of Sachiyo Minegishi to its board of directors, effective September 20. Ms. Minegishi will serve as Chair of the... Read More

Company will provide clinical overview and update on late-stage clinical candidate, nemvaleukin alfa, and overview of IL-18 pipeline program Clinicians to share expert perspectives around the potential of new cytokine-based immunotherapies Mural remains on track to deliver key data readouts in potentially registrational trials of nemvaleukin in platinum-resistant ovarian cancer and mucosal melanoma in 1H 2025 WALTHAM, Mass.... Read More

WALTHAM, Mass. and DUBLIN, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that on September 3, the Company granted to one newly hired employee (i) non-statutory stock options to purchase an aggregate of... Read More

WALTHAM, Mass. and DUBLIN, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that members of its management team will participate at two upcoming investor conferences and take 1x1 meetings. A webcast of both... Read More

Company remains well positioned to capitalize on the role of cytokines with near- and long-term potential value creation milestones, reiterates guidance on projected cash runway into Q4 2025 On track to report readouts from Mural’s lead asset, nemvaleukin alfa, in two late-stage clinical trials in 1H 2025 Presented clinical data from ARTISTRY-3 on less frequent dosing of nemvaleukin at the American Society of Clinical... Read More

WALTHAM, Mass. and DUBLIN, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that on August 1, the Company granted to one newly hired employee (i) non-statutory stock options to purchase an aggregate of... Read More

WALTHAM, Mass and DUBLIN, July 31, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced the appointment of George Golumbeski, Ph.D., to its board of directors effective July 30. “George has been a leader in business... Read More

WALTHAM, Mass. and DUBLIN, July 02, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that on July 1, the Company granted to four newly hired employees (i) non-statutory stock options to purchase an aggregate of... Read More

WALTHAM, Mass. and DUBLIN, June 05, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that Caroline Loew, Ph.D., CEO, will present at the East Coast IDEAS Investor Conference on June 13 at 9:15 a.m. EST. A webcast... Read More

WALTHAM, Mass. and DUBLIN, June 04, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that on June 3, the Company granted to two newly hired employees (i) non-statutory stock options to purchase an aggregate of 7,995... Read More

ARTISTRY-3 trial is being conducted to evaluate less frequent dosing of nemvaleukin alfa, Mural’s late-stage lead candidate Nemvaleukin demonstrated pharmacodynamic proof of mechanism in ARTISTRY-3 and was generally well-tolerated at all doses tested Less frequent dosing regimen, a shift from five daily infusions to two infusions per three-week cycle, is being evaluated as both a single agent and in combination with... Read More

Mural’s lead product candidate, nemvaleukin alfa, is in two potentially registrational trials in platinum resistant ovarian cancer and mucosal melanoma, both of which are on track with readouts expected in 1H 2025 A new, less frequent IV dose of nemvaleukin is also being evaluated both as a single agent and in combination with pembrolizumab in patients with cutaneous melanoma with preliminary data readouts anticipated in... Read More

WALTHAM, Mass and DUBLIN, May 03, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation and protein engineering to develop novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that on May 1, the Company granted to three newly... Read More

WALTHAM, Mass. and DUBLIN, Ireland, April 24, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced an upcoming poster presentation at the American Society of Clinical Oncology (ASCO) annual meeting taking place May... Read More

For the first time, the company shares data for its preclinical IL-18 and IL-12 programs—candidate nominations for each are expected later this year Combination of IL-18 binding protein resistance with additional half-life enhancement to IL-18 variant demonstrated durable immunological effects in preclinical models Data presented suggest dual-targeted, subunit approach to engineered IL-12 may mitigate cytokine’s hallmark... Read More

WALTHAM, Mass. and DUBLIN, Ireland, April 04, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation and protein engineering to develop novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that on April 1, the Company granted... Read More

Lead product candidate, nemvaleukin, is being developed to treat a wide range of solid tumors and is currently in two potentially registrational clinical trials with readouts for both expected in 1H 2025 Newly recommended phase 2 dose of nemvaleukin with increased dosage and less frequent dosing schedule to be explored in a cohort of ARTISTRY-6, the company’s ongoing phase 2 trial in patients with melanoma Mural Oncology... Read More

DUBLIN, Ireland, March 05, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced two upcoming poster presentations at the American Association for Cancer Research (AACR) annual meeting taking place April 5-10 in San... Read More

DUBLIN, Ireland, March 04, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation and protein engineering to develop novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that on March 1, the Company granted to two newly hired... Read More

DUBLIN, Ireland, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that CEO Caroline Loew, Ph.D. will present at the TD Cowen 44 th Annual Health Care Conference on March 5 th at 10:30am ET. A live webcast of... Read More

DUBLIN, Ireland, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation and protein engineering to develop novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that on February 2, the Company granted to two newly hired... Read More

Strategic changes to ARTISTRY-6 and ARTISTRY-7, both potentially registrational trials of nemvaleukin, are intended to result in more clinically meaningful data Mural intends to nominate development candidates for its engineered therapies targeting interleukin-18 and interleukin-12 programs in 2024 The Company reiterates current cash runway projection into 4Q 2025 DUBLIN, Ireland, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Mural... Read More